Sarepta shares rebound after shipments of gene therapy Elevidys resume in US

Sarepta Therapeutics' shares surged over 30% premarket after the company resumed U.S. shipments of its gene therapy, Elevidys, for ambulatory Duchenne muscular dystrophy patients. This decision, following an FDA recommendation that cleared the drug in a patient death probe, significantly alleviates financial headwinds and the risk of market withdrawal, enabling Sarepta to meet near-term obligations. However, shipments for non-ambulatory patients remain halted, and analysts anticipate potential near-term commercial hesitancy due to prior patient deaths and reputational concerns.

Analysis

Sarepta Therapeutics (SRPT) has experienced a significant positive catalyst with the resumption of U.S. shipments for its gene therapy, Elevidys, to ambulatory Duchenne muscular dystrophy patients. This development, which prompted a premarket share price surge of over 30%, directly addresses acute investor concerns by substantially reducing the near-term risk of a full market withdrawal for the company's primary revenue generator. The decision followed a U.S. FDA recommendation after a probe cleared the therapy in one patient death, enabling Sarepta to better meet its financial obligations to partners like Arrowhead (ARWR) and maintain access to debt facilities. However, significant risks remain, as shipments to non-ambulatory patients are still halted following two other patient deaths. Analysts caution that the recent negative headlines may create commercial hesitancy among patients and physicians, potentially dampening near-term revenue uptake despite the partial resumption of sales.

Key Decisions for Investors

• Investors should recognize that while the immediate risk of a full market withdrawal has diminished, the stock's valuation remains sensitive to lingering headwinds, particularly the halt for non-ambulatory patients and potential commercial hesitancy.
• Monitor upcoming sales data and physician commentary closely to gauge the actual market receptiveness to Elevidys post-controversy, as this will be a critical indicator of its true revenue potential.
• Further regulatory clarity from the FDA regarding the non-ambulatory patient population and any updates on shipment status from international partners like Roche are key future catalysts that will heavily influence the company's long-term growth trajectory.